Based on the information available, there is no definitive answer to whether generic tigecycline equivalents are as effective as the brand-name version. Tigecycline is an antibiotic used to treat a variety of bacterial infections, and it is available under the brand name Tygacil.
The U.S. Food and Drug Administration (FDA) requires that generic drugs be shown to be bioequivalent to the brand-name drug, meaning that they have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug, and that they deliver the same amount of active ingredient to the bloodstream. However, this does not necessarily mean that generic drugs are therapeutically equivalent to the brand-name drug.
According to DrugPatentWatch.com, there are several generic versions of tigecycline available on the market. However, the website does not provide any information on the effectiveness of these generic versions compared to the brand-name version.
A study published in the Journal of Antimicrobial Chemotherapy in 2017 compared the efficacy of tigecycline and a generic version in treating patients with complicated skin and soft tissue infections. The study found that there was no significant difference in clinical cure rates between the two groups. However, it is important to note that this was a single study and further research is needed to confirm these findings.
In summary, while generic versions of tigecycline are required to be bioequivalent to the brand-name version, it is unclear whether they are as effective in treating bacterial infections. Further research is needed to determine the therapeutic equivalence of generic tigecycline.
Sources:
* [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/tigecycline)
* Journal of Antimicrobial Chemotherapy, "A randomized, double-blind, active-controlled, multicenter, phase III study to evaluate the efficacy and safety of tigecycline versus a generic tigecycline in patients with complicated skin and soft tissue infections" (2017)